OL Oncology Letters 1792-1074 1792-1082 D.A. Spandidos 10.3892/ol.2016.4163 OL-0-0-4163 Articles Prognostic factors analysis in EGFR mutation-positive non-small cell lung cancer with brain metastases treated with whole brain-radiotherapy and EGFR-tyrosine kinase inhibitors WEIHANGPING 1 SUMENG 2 LINRUIFANG 2 LIHUIFANG 2 ZOUCHANGLIN 2 Department of Medical Oncology, Dongyang People's Hospital, Dongyang, Zhejiang 322100, P.R. China Department of Radiation Oncology and Chemotherapy, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China Correspondence to: Professor Changlin Zou, Department of Radiation Oncology and Chemotherapy, The First Affiliated Hospital of Wenzhou Medical University, 2 Fuxue Street, Wenzhou, Zhejiang 325000, P.R. China, E-mail: zcl19670115@163.com 03 2016 29 01 2016 11 3 2249 2254 09122014 15012016 Copyright © 2016, Spandidos Publications 2016

The survival time of non-small cell lung cancer (NSCLC) patients with brain metastases has been previously reported to be 6.5–10.0 months, even with systematic treatment. Patients that possess a certain epidermal growth factor receptor (EGFR) mutation alongside NSCLC with brain metastases also have a short survival rate, and a reliable prognostic model for these patients demonstrates a strong correlation between the outcome and treatment recommendations. The Cox proportional hazards regression and classification tree models were used to explore the prognostic factors in EGFR mutation-positive NSCLC patients with brain metastases following whole-brain radiation therapy (WBRT) and EGFR-tyrosine kinase inhibitor (EGFR-TKI) treatment. A total of 66 EGFR mutation-positive NSCLC patients with brain metastases were retrospectively reviewed. Univariate and multivariate analyses by Cox proportional hazards regression were then performed. The classification tree model was applied in order to identify prognostic groups of the patients. In the survival analysis, age, carcinoembryonic antigen (CEA) and status of the primary tumor were prognostic factors for progression free survival (P=0.006, 0.014 and 0.005, respectively) and overall survival (P=0.009, 0.013 and 0.009, respectively). The classification tree model was subsequently applied, which revealed 3 patient groups with significantly different survival times: Group I, age <65 years and CEA ≤10 µg/ml; Group II, age <65 years and CEA >10 µg/ml or age ≥65 years and CEA ≤10 µg/ml; and Group III, age ≥65 years and CEA >10 µg/ml. The major prognostic predictors for EGFR mutation-positive NSCLC patients with brain metastases following WBRT and EGFR-TKI were age and CEA. In addition, primary tumor control may be important for predicting survival.

 non-small cell lung cancer brain metastases epidermal growth factor receptor mutation-positive classification tree model prognostic factors Introduction

Patients with non-small cell lung cancer (NSCLC) possess a high risk of developing brain metastases. The incidence rate of brain metastases for patients with lung cancer is 23–65% (1). Once intracerebral metastases develop, the prognosis is poor. The median survival time for patients with untreated brain metastases is only ~1 month (2,3). The principle therapeutic modality for brain metastases is whole-brain radiation therapy (WBRT), and the median survival time following this treatment may increase to 4–6 months. Although therapies, including surgery, WBRT, stereotactic radiotherapy and systematic chemotherapy, are rapidly improving, the prognosis of patients with brain metastases from lung cancer remains poor, and the median survival time for patients remains at ~6.5–10 months (4–7).

In 2004, the genes encoding the read code box of epidermal growth factor receptor (EGFR) were sequenced (8). In addition, the gene mutation status has been elucidated and is now widely used in clinical practice. As a result, the identification of the EGFR mutation and the introduction of treatment with EGFR-tyrosine kinase inhibitors (EGFR-TKI) has improved clinical outcomes (9). EGFR-TKI regimens have a good efficacy against brain metastases in NSCLC. In previous years, increasing efforts have been made to understand and use prognostic indicators in patients with brain metastases from NSCLC (9,10). However, the prognostic factors of EGFR mutation-positive NSCLC patients with brain metastases following WBRT have not been studied extensively.

Based on the aforementioned considerations, the purpose of the present study was to analyze and assess the prognostic factors in EGFR mutation-positive NSCLC patients with brain metastases following WBRT and EGFR-TKI treatment, using the classification tree and Cox proportional hazards regression models.

 Materials and methods <sec> <title>Patients

Between January 2005 and July 2014, 66 EGFR mutation-positive patients diagnosed with NSCLC were identified with brain metastases and treated at the Department of Radiation Oncology and Chemotherapy at The First Affiliated Hospital of Wenzhou Medical University (Wenzhou, China). The criteria for inclusion in the present retrospective study were as follows: i) All patients possessed a histopathological diagnosis of NSCLC, acquired by bronchial biopsy, fine needle aspiration biopsy or a surgical excision specimen; ii) all brain metastasis diagnoses were confirmed by head magnetic resonance imaging (MRI), contrast-enhanced computed tomography (CT) or positron emission tomography (PET)/CT scans; iii) the EGFR gene mutation was detected; iv) all patients were treated with EGFR-TKI until the disease progressed or the toxicity was intolerable; v) all patients were treated with WBRT (typically 30 gray units per 10 fractions); vi) all survival data were up to date on July 31, 2014; and vii) the clinical data of all patients were complete. In total, 66 patients were available for the present analysis, 34 of which were males and 32 were females. The median age at the diagnosis of brain metastasis was 61 years old (range, 38–82 years). A total of 11 (16.7%) patients possessed squamous cell lung carcinoma, while 55 (83.3%) patients possessed adenocarcinoma.

 Study design

The first section of the present study was a retrospective description regarding the recent therapeutic effects and long-term treatment effects observed in the patients. The second section of the study was a multivariate analysis that followed a univariate analysis, including 14 prognostic factors, using Cox proportional hazards regression. The final section of the study was a classification tree model.

The following variables were examined to determine the prognostic value for EGFR mutation-positive NSCLC patients with brain metastases following WBRT and EGFR-TKI treatment: i) Age at diagnosis of brain metastasis (for statistical purposes, the patients were classified into two age groups, <65 vs. ≥65 years); ii) gender (male vs. female); iii) Eastern Cooperative Oncology Group performance status (ECOG PS; PS ≤2 vs. >2 points); iv) histopathology (adenocarcinoma vs. squamous cell carcinoma); v) primary tumor node metastasis (TNM) stage (I–III vs. IV stage); vi) smoking (heavy vs. no/little); vii) history of pulmonary lesions radiotherapy (with vs. without); viii) history of pulmonary lesions surgical resection (with vs. without); ix) cisplatin-based chemotherapy (with vs. without); x) number of brain metastases (single vs. multiple); xi) extracranial metastases (with vs. without); xii) carcinoembryonic antigen (CEA) levels at brain metastases diagnosis (for statistical purposes, the patients were classified into two groups, ≤10 µg/ml vs. >10 µg/ml); xiii) the status of the primary tumor (controlled vs. uncontrolled); and xiv) supportive chemotherapy (yes vs. no). No/little smoking was defined as a smoking index (SI) of <200 (11). SI was defined as the number of cigarettes smoked per day multiplied by the number of years smoked.

 Evaluation

The therapeutic effects were evaluated using the RECIST 1.1 criteria (12). The therapeutic effects may be divided into complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD). The objective response rate (ORR) refers to the percentage of CR+PR patients out of the total number of patients, and the disease control rate (DCR) refers to the percentage of CR+PR+SD patients out of the total number of patients. The long-term treatment effects were evaluated by recording the progression free survival (PFS) and overall survival (OS) rates. PFS was defined as the interval between the diagnosis of brain metastasis and the initial observation of PD or mortality from any cause. The OS was measured between the date of the diagnosis of brain metastasis and the time of the mortality of the patient or the deadline for the study (July 31, 2014).

 Statistical analysis

The clinical data were described by median, frequency and percentage. Survival analyses for each prognostic factor were performed using the Kaplan-Meier method, using SPSS software version 19.0 (IBM SPSS; Armonk, NY, USA). The log rank test was used in statistical comparisons. The multivariate analysis was conducted using the Cox proportional hazard regression model. The classification tree model was subsequently applied. A P-value of <0.05 was considered to indicate a statistically significant difference.

 Results <sec> <title>Statistical description

A total of 66 patients were analyzed. Of these, 3 patients achieved CR, 27 patients demonstrated a PR, 25 patients remained to possess SD and 11 patients developed a PD; therefore, the patients demonstrated an ORR of 45.5% (30/66) and a DCR of 83.3% (55/66). At the time of analysis, 5 patients (7.58%) were alive, while 61 patients (92.42%) had succumbed. The median PFS was 5.9 months (95% CI, 4.2–8.8 months) and the median survival time of the entire cohort was 10.9 months (95% CI, 8.7–14.1 months). The survival curve for EGFR mutation-positive NSCLC patients with brain metastases is shown in Fig. 1.

 Survival analysis

In the univariate analysis, the following variables at the diagnosis of brain metastasis were significantly associated with an improved PFS and OS (P-values, respectively): Age (0.008, 0.028); CEA (0.035, 0.031); and the status of primary tumor (0.015, 0.026). The prognostic factors for PFS and OS in the univariate analysis are presented in Table I.

In the multivariate analysis, the prognostic predictors for PFS for EGFR mutation-positive NSCLC patients with brain metastases were age, CEA and status of the primary tumor (P=0.006, 0.014 and 0.005, respectively). Age, CEA and status of the primary tumor were also predictive factors for OS (P=0.009, 0.013 and 0.009, respectively). The results of the prognostic factors for PFS and OS in the multivariate analysis are summarized in Tables II and III.

Classification tree model. Based on the clinical data, a classification and regression tree method (13,14), a non-parametric regression method, was used. In addition, the method selected the automatic depth, which was length of the classification tree model. The terminal parent and child nodes were defined as 20 and 10, respectively. The adjusted significance level was defined as P<0.05 in the splitting and merging of a tree branch. The nodes were combined into the same group where the significance level of the statistical difference between the survival distributions of two terminal nodes was >0.05.

Following the application of the classification tree model, a survival tree was generated (Fig. 2), in which the first prognostic split occurred between patients aged <65 years vs. ≥65 years. Within patients aged <65 years or ≥65 years, the CEA level at the diagnosis of brain metastasis (≤10 µg/ml vs. >10 µg/ml) became a dividing factor, finally resulting in four groups. No significant difference in the survival time between groups 2 and 3 was identified (P=0.962; Fig. 2). Therefore, groups 2 and 3 were combined. Finally, the patients were divided into three groups: Group I, age <65 years and CEA ≤0 µg/ml; Group II, age <65 years and CEA >10 µg/ml or age ≥65 years and CEA ≤10 µg/ml; and Group III, age ≥65 years and CEA >10 µg/ml. The survival curves for the three groups that were determined by classification tree analysis are shown in Fig. 3 (P=0.004).

 Discussion

The brain is one of the most common sites of metastasis in patients with lung cancer, and lung cancer is the most common intracranial metastatic tumor (15). The incidence of brain metastases in lung cancer is 20% at diagnosis and 40% at autopsy (16). In addition, brain metastases contribute to increased morbidity and mortality and herald a poor prognosis in patients with metastatic lung cancer (16). WBRT continues to be an important palliative treatment option for patients with brain metastases from NSCLC. In previous studies, WBRT combined with EGFR-TKI treatment was demonstrated to be a safe and effective treatment for EGFR mutation-positive NSCLC patients with brain metastases, with a median survival time of 7.7–13.0 months (9,17,18). The median survival time in the present analysis was 10.9 months, which confirms these expectations. Predicting the survival time of patients is important, and the fact that a significant percentage of patients have a limited survival time suggests that accurate survival prediction models may assist in avoiding overtreatment (19,20).

In 1997, the Radiation Therapy Oncology Group established the prognostic scores recursive partitioning analysis (RPA) classification, which was the first prognostic scoring system for assessing the prognosis of patients with brain metastases (21–23). The detailed parameters of the model contained age, Karnofsky performance status (KPS), with or without extracranial metastases and the status of the primary tumor. Later, other established prognostic scores, including the basic score for brain metastases, systemic inflammatory response and graded prognostic assessment, were developed for the general population of patients with brain metastases.

Previous studies have demonstrated several prognostic factors in NSCLC patients with brain metastases. Gerosa et al (23) concluded that the performance status, age, extracranial metastases and primary tumor control caused a potential effect on survival. Zindler et al (24) revealed the prognostic value of performance status, age, absence of extracranial metastases, primary tumor site, gender and steroid response for OS. Rotin et al (25) indicated that the factors influencing survival were the number of brain metastases and KPS. Rades et al (26) revealed that the prior performance status, a younger age and the absence of extracranial metastases were associated with increased survival time. Therefore, in numerous published studies, age was commonly manifested as a prognostic factor. Additionally, patients having no PD in in the lung tumor was commonly mentioned as a prognostic factor.

The present Cox proportional hazards regression analysis of an EGFR mutation-positive NSCLC patient population with brain metastases confirmed that the prognostic implications of age (<65 years), CEA (≤10 µg/ml) and primary tumor control were favorable factors for survival time. Unlike previous studies, the clinical value of CEA in the prognosis of EGFR mutation-positive NSCLC patients with brain metastases was indicated to be extremely important. Recently, Fiala et al (27) showed that an increased level of CEA and CYFRA21-1 may be associated with a poor outcome for patients with NSCLC that are treated with erlotinib. These findings indicate that tumor biomarkers may be used for predicting the effect of therapy and the prognosis of patients.

Previous studies that investigated the prognostic factors of patients with brain metastases from NSCLC have indicated that traditional models focus on assessing the relative prognostic factors using the Cox proportional hazards regression model. A previous study indicated that, in combination with Cox proportional hazards regression, the survival tree method may aid prognostic analysis (28). To the best of our knowledge, none of the published prognostic classification models have involved EGFR mutation-positive NSCLC patients with brain metastases.

The present study aimed to use the Cox proportional hazards regression and classification tree models to analyze and explore prognostic factors in EGFR mutation-positive NSCLC patients, following WBRT and EGFR-EKI treatment. Age and CEA were the dominant prognostic factors identified in the classification tree model. Combining the aforementioned results of the Cox proportional hazard regression model, age (≥65 years) and CEA (>10 µg/ml) were considered to be adverse prognostic factors. In particular, the present analysis succeeded in splitting patients with brain metastases from EGFR mutation-positive NSCLC into three groups. The identification of prognostic groups between patients may provide prognostic information and serve as a basis of classification for future trials. In addition, the primary tumor status was indicated to be a prognostic factor in the Cox proportional hazards regression analysis. However, as the third dividing factor of the classification tree model, primary tumor control may be used a good predictor of prognosis, but may not be as reliable as age and CEA.

Regarding the present study, additional prospective studies are recommended to be performed in order to increase the accuracy of the results. Ideally, the sample size would have been larger. In conclusion, the major prognostic predictors of EGFR mutation-positive NSCLC patients with brain metastases following WBRT and EGFR-TKI were age and CEA. Age (≥65 years) and CEA (>10 µg/ml) were considered to be the adverse prognostic factors. In addition, primary tumor control may be important for predicting survival.

 Acknowledgements

The authors would like to acknowledge the following people, who have made the completion of the present study possible: Professor Changlin Zou, for vital guidance and support, and Mr. Lucheng Zhu, for encouragement and assistance.

 Abbreviations EGFR

epidermal growth factor receptor

 NSCLC

non-small cell lung cancer

 WBRT

whole-brain radiation therapy

 EGFR-TKI

epidermal growth factor receptor-tyrosine kinase inhibitors

 References KongDSLeeJINamDHParkKKimJHKimJGParkJOParkKPrognosis of non-small cell lung cancer with synchronous brain metastases treated with gamma knife radiosurgeryJ Korean Med Sci21527532200610.3346/jkms.2006.21.3.52716778400 ZimmSWamplerGLStableinDHazraTYoungHFIntracerebral metastases in solid-tumor patients: Natural history and results of treatmentCancer48384394198110.1002/1097-0142(19810715)48:2<384::AID-CNCR2820480227>3.0.CO;2-87237407 YangLParkinDMFerlayJLiLChenYEstimates of cancer incidence in China for 2000 and projections for 2005Cancer Epidemiol Biomarkers Prev14243250200515668501 GasparLScottCRotmaIlMAsbellSPhillipsTWassermanTMcKennaWGByhardtRRecursive partitioning analysis (RPA) of prognostic factors in three radiation therapy oncology group (RTOG) brain metastases trialsInt J Radiat Oncol Biol Phys37745751199710.1016/S0360-3016(96)00619-09128946 LagerwaardFJLevendagPCNowakPJEijkenboomWMHanssensPESchmitzPIPrognostic factors in patients with brain metastases: A review of 1292 patientsInt J Radiat Oncol Biol Phys43795803199910.1016/S0360-3016(98)00442-810098435 PengHMaMHanBSurvival analysis of 1,742 patients with stage IV non-small cell lung cancerZhongguo Fei Ai Za Zhi143623662011(In Chinese)21496437 MekhailTSombeckMSollaccioRAdjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: Results of the EORTC 22952–26001 studyCurr Oncol Rep13255258201110.1007/s11912-011-0180-121584645 PaoWMillerVZakowskiMDohertyJPolitiKSarkariaISinghBHeelanRRuschVFultonLEGF receptor gene mutations are common in lung cancers from ‘never smokers’ and are associated with sensitivity of tumors to gefitinib and erlotinibProc Natl Acad Sci USA1011330613311200410.1073/pnas.040522010115329413 NiederNBremnesRMAndratschkeNHPrognostic scores in patients with brain metastases from non-small cell lung cancerThorac Oncol413371341200910.1097/JTO.0b013e3181b6b6f4 AbaciogluUCaglarHAtasoyBMAbdulloevTAkgunZKilicTGamma knife radiosurgery in non small cell lung cancer patients with brain metastases: Treatment results and prognostic factorsJ BUON15274280201020658721 YuPJChenWGFengQLChenWJiangMJLiZQAssociation between CYP1B1 gene polymorphisms and risk factors and susceptibility to laryngeal cancerMed Sci Monit21239245201510.12659/MSM.89308425619313 EisenhauerEATherassePBogaertsJSchwartzLHSargentDFordRDanceyJArbuckSGwytherSMooneyMNew response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)Eur J Cancer45228247200910.1016/j.ejca.2008.10.02619097774 GassKKleinMSarnatSEWinquistADarrowLAFlandersWDChangHHMulhollandJATolbertPEStricklandMJAssociations between ambient air pollutant mixtures and pediatric asthma emergency department visits in three cities: A classification and regression tree approachEnviron Health1458201510.1186/s12940-015-0044-526123216 RovliasATheodoropoulosSPapoutsakisDChronic subdural hematoma: Surgical management and outcome in 986 cases: A classification and regression tree approachSurg Neurol Int6127201510.4103/2152-7806.16178826257985 KongDSLeeJINamDHParkKKimJHKimJGParkJOParkKPrognosis of non-small cell lung cancer with synchronous brain metastases treated with gamma knife radiosurgeryJ Korean Med Sci21527532200610.3346/jkms.2006.21.3.52716778400 EbertBLNiemierkoEShaffeKSalgiaRUse of temozolomide with other cytotoxic chemotherapy in the treatment of patients with recurrent brain metastases from lung cancerOncologist86975200310.1634/theoncologist.8-1-6912604733 ArrietaOVillarreal-GarzaCZamoraJBlake-CerdaMde la MataMDZavalaDGMuñiz-HernándezSde la GarzaJLong-term survival in patients with non-small cell lung cancer and synchronous brain metastasis treated with whole-brain radiotherapy and thoracic chemoradiationRadiat Oncol6166201110.1186/1748-717X-6-16622118497 MaSXuYDengQYuXTreatment of brain metastasis from non-small cell lung with whole brain radiotherapy and gefitinib in a Chinese populationLung Cancer65198203200910.1016/j.lungcan.2008.10.02819091441 LockMChowEPondGRDoVDanjouxCDinniwellRLeaJBezjakAPrognostic factors in brain metastases: Can we determine patients who do not benefit from whole-brain radiotherapyClin Oncol (R Coll Radiol)16332338200410.1016/j.clon.2004.03.00615341436 XiangZChenJZhangHShenLWeiQWhole brain radiotherapy-based combined modality treatment of brain metastases from non-small cell lung cancer: A retrospective analysis of prognostic factorsOncol Res Treat383540201510.1159/00037150125634677 GasparLScottCRotmanMAsbellSPhillipsTWassermanTMcKennaWGByhardtRRecursive partitioning analysis (RPA) of prognostic factors in three radiation therapy oncology group (RTOG) brain metastases trialsInt J Radiat Oncol Biol Phys3774551199710.1016/S0360-3016(96)00619-09128946 GasparLEScottCMurrayKCurranWValidation of the RTOG recursive partitioning analysis (RPA) classification for brain metastasesInt J Radiation Oncol Biol Phys4710011006200010.1016/S0360-3016(00)00547-2 GerosaMNicolatoAForoniRTomazzoliLBricoloAAnalysis of long-term outcomes and prognostic factors in patients with non-small cell lung cancer brain metastases treated by gamma knife radiosurgeryJ Neurosurg102Suppl7580200510.3171/jns.2005.102.s_supplement.007515662785 ZindlerJDRodriguesGHaasbeekCJDe HaanPFMeijerOWSlotmanBJLagerwaardFJThe clinical utility of prognostic scoring systems in patients with brain metastases treated with radiosurgeryRadiother Oncol106370374201310.1016/j.radonc.2013.01.01523522151 RotinDLPaklinaOVKobiakovGLShishkinaLVKravchenkoÉVStepanianMALung cancer metastases to the brain: Clinical and morphological prognostic factorsZh Vopr Neirokhir Im N N Burdenko7724282013(In Russian), discussion 2923659117 RadesDSchildSELohynskaRVeningaTStalpersLJDunstJTwo radiation regimens and prognostic factors for brain metastases in non-small cell lung cancer patientsCancer11010771082200710.1002/cncr.2287717614294 FialaOPessekMFinekJBenesovaLMinariKMBortlicekZTopolcanOPredictive role of CEA and CYFRA21-1 in patients with advanced-stage NSCLC treated with erlotinibAnticancer Res3432053210201424922695 SchillingCMortimerDDalzielKHeeleyEChalmersJClarkePUsing Classification and Regression Trees (CART) to identify prescribing thresholds for cardiovascular diseasePharmacoeconomicsNov172015(Epub ahead of print)

Survival curve of epidermal growth factor receptor mutation-positive non-small cell lung cancer patients with brain metastases. Cum., cumulative.

Classification tree model was used for EGFR mutation-positive non-small cell lung cancer patients with brain metastases following whole-brain radiation therapy and EGFR-tyrosine kinase inhibitors. EGFR, epidermal growth factor receptor; N, number of patients; CEA, carcinoembryonic antigen.

Survival curves of the three groups that were determined by classification tree analysis (log rank test; P=0.004). Cum., cumulative.

Prognostic factors for PFS and OS in univariate analysis.

Prognostic factors No. of patients PFSa PFS P-value OSa OS P-value
Age, years
<65 40 8.7 0.008 13.2 0.028
≥65 26 3.4   9.0
Gender
  Male 34 6.9 0.481 10.1 0.929
  Female 32 4.6 11.0
ECOG PS
  ≤2 48 6.7 0.424 11.4 0.348
  >2 18 3.2   4.1
Primary TNM stage
  I–III 15 3.3 0.314   6.2 0.125
  IV 51 7.1 11.3
Histopathology
  Adenocarcinoma 55 6.2 0.341 10.9 0.455
  Squamous cell carcinoma 11 5.7   7.7
Smoking
  Heavy 24 8.7 0.478 11.1 0.427
  No/little 42 4.6 10.7
Pulmonary lesions radiotherapy
  With 12 4.6 0.464   9.0 0.514
  Without 54 6.1 10.9
Pulmonary lesions surgical resection
  With   6 7.5 0.189 11.7 0.512
  Without 60 5.6 10.9
Cisplatin-based chemotherapy
  With 37 6.3 0.340 11.3 0.823
  Without 29 3.6   9.9
Brain metastases
  Single 22 6.0 0.538 11.2 0.715
  Multiple 44 5.4 10.7
Extracranial metastases
  With 35 6.2 0.747 11.0 0.441
  Without 31 4.4   9.4
CEA, µg/ml
  ≤10 27 9.3 0.035 16.0 0.031
  >10 39 4.1   8.7
Primary tumor status
  Uncontrolled 15 2.7 0.015   6.7 0.026
  Controlled 51 7.1 11.3
Supportive chemotherapy
  Yes 24 5.4 0.450 11.6 0.731
  No 42 7.5 10.6

Data measured in months. PFS, progression free survival; OS, overall survival; ECOG PS, Eastern Cooperative Oncology Group performance status; TNM, tumor node metastasis; CEA, carcinoembryonic antigen.

Multivariate analysis of prognostic factors for progression free survival.

Variable B SE Wald Exp (B) P-value
Age, years −0.721 0.261 7.664 0.486 0.006
CEA, µg/ml −0.652 0.266 6.003 0.521 0.014
Primary tumor status   0.872 0.312 7.807 2.391 0.005

CEA, carcinoembryonic antigen; B, coefficient for the constant; SE, standard error; Wald, Wald χ2 test; Exp (B), exponentiation of B.

Multivariate analysis of prognostic factors for overall survival.

Variable B SE Wald Exp (B) P-value
Age, years −0.706 0.272 6.738 0.494 0.009
CEA, µg/ml −0.674 0.271 6.178 0.510 0.013
Primary tumor status   0.818 0.313 6.855 2.267 0.009

CEA, carcinoembryonic antigen; B, coefficient for the constant; SE, standard error; Wald, Wald χ2 test; Exp (B), exponentiation of B.